Vita Life Sciences Limited (ASX:VLS)
Australia · Delayed Price · Currency is AUD 2.520
-0.080 (-3.08%)
At close: Mar 4, 2026
Vita Life Sciences Revenue
In the year 2025, Vita Life Sciences had annual revenue of 93.27M AUD with 17.31% growth. Vita Life Sciences had revenue of 47.73M in the half year ending December 31, 2025, with 22.42% growth.
Revenue
93.27M
Revenue Growth
+17.31%
P/S Ratio
1.49
Revenue / Employee
266.49K
Employees
350
Market Cap
139.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 93.27M | 13.77M | 17.31% |
| Dec 31, 2024 | 79.51M | 6.08M | 8.28% |
| Dec 31, 2023 | 73.43M | 6.54M | 9.78% |
| Dec 31, 2022 | 66.89M | 9.78M | 17.14% |
| Dec 31, 2021 | 57.10M | 10.62M | 22.85% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vitura Health | 129.24M |
| Medical Developments International | 40.64M |
| Little Green Pharma | 38.49M |
| ECS Botanics Holdings | 19.36M |
| IDT Australia | 19.00M |
| Peak Processing | 14.59M |
| Cann Group | 13.25M |
| Epsilon Healthcare | 9.39M |